Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | PPARD | Q03181 | 2/20 | 0.58 |
| ▸ | PPARG | P37231 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.55 |
| ▸ | ESR1 | P03372 | 1/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | PPARA | Q07869 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.53 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13616217 | 0.94 | PPARD (0.67) | ALOX15PPARDPPARGALDH1A1CYP19A1 | |
| SCHEMBL274850 | 0.94 | ALOX15 (0.68) | ALOX15ALDH1A1CYP19A1ESR1FFAR1 | |
| SCHEMBL2780802 | 0.92 | ALOX15 (0.71) | ALOX15PPARDPPARGALDH1A1FFAR1 | |
| Butanone SCHEMBL21796224 | 0.90 | ESR1 (0.58) | ALOX15PPARDPPARGALDH1A1CYP19A1 | |
| Formaldehyde SCHEMBL30592324 | 0.88 | ALOX15 (0.61) | ALOX15ALDH1A1CYP19A1ESR1FFAR1 | |
| SCHEMBL10622949 | 0.87 | PPARD (0.58) | ALOX15PPARDPPARGALDH1A1CYP19A1 | |
| Chloroacetic Acid SCHEMBL7821121 | 0.86 | ALOX15 (0.59) | ALOX15PPARDPPARGALDH1A1CYP19A1 | |
| SCHEMBL422442 | 0.86 | ALOX15 (0.76) | ALOX15PPARDPPARGALDH1A1FFAR1 | |
| SCHEMBL339492 | 0.85 | ALOX15 (0.81) | ALOX15PPARDPPARGALDH1A1FFAR1 | |
| SCHEMBL1550206 | 0.85 | FFAR1 (0.77) | ALOX15ALDH1A1CYP19A1ESR1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2313360-B1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | UNIV SYDDANSK (DK) | 2012-09-05 | — | — | EP | disclosed |
| US-20110152315-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | SYDDANSK UNIVERSITET | 2011-06-23 | — | — | US | disclosed |
| US-7417169-B2 | Amino alcohol derivatives, medicinal composition containing the same, and use of these | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-08-26 | — | — | US | disclosed |
| US-20070078184-A1 | Amino alcohol derivatives, medicinal composition containing the same, and use of these | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-04-05 | — | — | US | disclosed |
| EP-1679304-A1 | AMINO ALCOHOL DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND USE OF THESE | Kissei Pharmaceutical Co., Ltd. (JP) | 2006-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152315-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | GPR119, INSR, GPR65 | ALOX15 763/4885PPARD 106/4885PPARG 42/4885 |
| US-20070078184-A1 | Amino alcohol derivatives, medicinal composition containing the same, and use of these | ADRB2, ADRA2A, ADRA1A | ALOX15 1356/4885PPARD 1403/4885PPARG 570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.